drugset
drugset / Trial / NCT00743015

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

NCT00743015 ↗

Phase 1 Completed 19 enrolled Boehringer Ingelheim
CrossoverTreatment

Summary

The general aim is to evaluate the relative oral bioavailability of BI 44370 TA tablets during and between migraine attacks as well as Safety, Tolerability and Pharmacokinetic

Timeline

Start
2008-09
Primary completion
2009-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44370 Small molecule 200 mg Oral

Indications

migraine disorder